Erasmus MC Biomedical Fund

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.

CAVΛDIS™ is a Dutch biomedical company active in the field of cardiovascular risk assessment. They develop prognostic tests to identify patients at risk of cardiovascular and disease. The company identified several novel biomarkers predictive for cardiovascular events. It is their goal is to develop clinically meaningful risk stratification tools that will help personalize treatment and achieve better patient outcomes.

Therosteon is a new biotech fledgling emerging from the Erasmus Medical Center in Rotterdam (The Netherlands). The Company develops novel therapeutics for bone diseases including osteoporosis, osteoarthritis, and bone metastasis based on its OsteoBLAST technology platform. Bone diseases represent an interesting market opportunity, with huge unmet medical needs. Osteoporosis in itself represents a huge market opportunity with drug sales totaling 7 billion. Therosteon is located in incubator facilities of the Erasmus MC and collaborates closely with academic group of its scientific founder Prof. Hans van Leeuwen.

RiverD International B.V. offers innovative solutions for unmet needs in healthcare and life sciences research. Their products are based on dedicated application and optimization of Raman spectroscopy for the analysis of cells and tissues. They put the power of this non-invasive, reagent-less optical technology into your hands, providing you with the information you need.